MINDCURE’s Update Hints At Big Things To Come

  • As psychedelic stock performance suddenly picks up, Mind Cure Health stands out as one of the biggest bargains
  • Its November 4th corporate update, reports strong progress on iSTRYM commercialization and exciting news in drug development

Mind Cure Health (CAN:MCUR / US:MCURF) has just released a new corporate update. Its iSTRYM platform is exceeding initial penetration targets, ibogaine manufacturing is on track, and an interesting new drug development initiative is on the near-term horizon.

More on this later. In many ways, MINDCURE is representative of the emerging psychedelic drug industry.

By coincidence, MINDCURE commenced trading as a public company on September 21, 2020, one trading day after the IPO of Compass Pathways (US:CMPS). As all investors in psychedelic stocks already know, the Compass IPO sparked a huge rally in psychedelic stocks.

MINDCURE rose with the industry. From an initial trading price of CAD$0.20, MCUR soared to a 2020 high of CAD$1.09.

Following that peak, just like the rest of the industry, MINDCURE has seen its stock slide to much lower levels in 2021. However (like many other companies), the Company capitalized on that big 2020 rally to raise a large amount of capital – at an attractive price for shareholders.

Today, MCUR sits at CAD$0.31 and the Company has a market cap of CAD$29.06 million, despite recently reporting cash and equivalents of CAD$15.6 million. That’s a very lean cash-to-market-cap ratio of less than 2:1, one of the lowest in the industry.

A value-packed company in an industry ready to rally

However, the disappointing market conditions for existing shareholders in the psychedelic drug industry are an opportunity for new investors. As Psychedelic Stock Watch recently observed, the industry appears to be on the verge of a broad, new rally.
What does MINDCURE have to offer new investors, apart from being cash-rich and being positioned in an emerging industry that represents the best investment opportunity in life sciences?

The update just released by MINDCURE spells out what the Company has been doing with the capital it raised over the past year. It also points investors toward where management has been building value.

The value proposition for MINDCURE starts with iSTRYM. iSTRYM is MINDCURE’s proprietary digital therapeutics platform.

The initial version of the platform is not only launched, it’s being deployed in mental health treatment clinics in North America and Europe. On August 26th, MINDCURE announced the initial release of iSTRYM.

The Company set aggressive goals for the distribution and adoption of iSTRYM by mental health providers: 10 clinics by Q4 of 2021 and 150 clinics by the end of 2022.

The November 4th update reports that MINDCURE is ahead of schedule with its minimum viable product (MVP), already having partnered with 20 ketamine clinics in nine U.S. states and three Canadian provinces.

With MINDCURE now having 20 clinic partners in place for iSTRYM only 10 weeks after the initial release, this also puts the Company on track to meet its larger goal: full commercial deployment in Q1 2022 and 150 partner clinics for iSTRYM by the end of 2022.

Digital therapeutics is the future of healthcare

Investors familiar with this industry know that active players in psychedelics-assisted mental health therapy (both public and private) have been busy lining up a digital therapeutics platform to support their treatment model.

Digital therapeutics is rapidly becoming big business in healthcare for two reasons.
  1. General improvements in efficiency: online portals to streamline everything from scheduling appointments to monitoring medication regimens
  2. New, next-generation digital therapeutics platforms are incorporating AI into their software, which allows practitioners to both expedite and improve on patient treatment

MINDCURE spent much of the last year assembling and integrating the components of its own, proprietary platform. Today, the Company (and shareholders) are preparing to reap the rewards.

President and CEO, Kelsey Ramsden telegraphed MINDCURE’s overall strategy for investors back at the end of April.
“MINDCURE recognizes the value of blue sky opportunities in drug development and while we pursue the establishment of a clearly differentiated research program from other psychedelic companies, leading with synthesizing ibogaine, we believe strongly that bottom line fundamentals are essential, and that is why we are developing horizons of realizable revenue through a planned global SaaS rollout with iSTRYM anticipated to become a platform backbone of the psychedelic-assisted psychotherapy industry with our AI driven technology.” [emphasis mine]

Microdose, an industry icon in terms of both investor education and as a frequent host for public and private companies in its virtual investor conferences, is one of the believers in iSTRYM. Microdose has nominated MINDCURE as “B2B Tech Company of the Year” in the psychedelics space.

However, MINDCURE is much more than just a software company. The Company has been steadily building value for shareholders with both its proprietary production of synthetic ibogaine and its drug development initiatives.

Synthetic ibogaine production (and distribution) remains on track. MINDCURE’s GLP (“Good Laboratory Practice”) synthetic ibogaine is expected to be available by Q2 2022. MINDCURE is also seeking to leverage this synthetic product into drug development opportunities.

Two ibogaine-based drug candidates, MC-106 and MC-808 have been selected for internal development. Investors can expect to hear more about these programs by Q2 of 2022.

Targeting 2022 Phase II clinical trial

Perhaps the most-exciting recent news for MINDCURE in drug development concerns its previous announcement on “The Desire Project”.

MINDCURE is working on an MDMA-assisted treatment targeting female hypoactive sexual desire disorder. With an estimated treatment population of 9.5 million premenopausal women in the United States alone, this is a major untapped treatment market.

In MINDCURE’s November 4th update, the Company revealed its latest progress here.
  1. Expecting a pre-IND meeting with the FDA by Q1 2022
  2. Aiming for commencement of a Phase IIa clinical trial by Q3 of 2022

Mind Cure Health has been flying under the radar for most of 2021. As its iSTRYM footprint starts to rapidly expand, that’s quickly changing.

With $15+ million in cash, a strong growth trajectory, and an exciting business plan, today’s CAD$29 million market cap is overdue for a large jump higher.

For investors in psychedelic stocks who are interested in even more information on MINDCURE, Psychedelic Stock Watch will be releasing a Q&A with President and CEO, Kelsey Ramsden in the near future.

DISCLOSURE: The writer holds shares in Mind Cure Health. Mind Cure Health is a client of Psychedelic Stock Watch.

Please see our full PRIVACY POLICY

The content on Psychedelic Stock Watch is not personalized investment advice. Our employees strive to give smart, stimulating commentary, but are not licensed to address or give advice on individual investment situations. Nothing you receive from Psychedelic Stock Watch should be considered personal investment advice. Any investments recommended by Psychedelic Stock Watch should only be made after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. All investments carry risk of significant loss.

Please see full disclaimers at https://psychedelicstockwatch.com/disclaimer applicable to all content provided by PSW , wherever published or re-published: https://psychedelicstockwatch.com/statements-policies

Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. PsychedelicStockWatch.com (PSW) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.

PSW receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to PSW and may hire additional publishers or advertisers on behalf of the issuer. PSW retains any excess sums after expenses as its compensation. PSW may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus PSW and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.

PSW and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; PSW is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.

This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or PSW or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at http://www.sec.gov where readers can review all public filings submitted by the issuer. PSW is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.

MINDCURE_iSTRYM by Psychedelic Stock Watch is licensed under N/A


Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry

Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now

© 2019 - 2022 Psychedelic Stock Watch, Privacy Policy, Disclaimer